|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Asymptomatic male with grade 3 left varicocele and two children desiring vasectomy with low testosterone显示文摘 | Renato Fraietta Daniel Suslik Zylbersztejn Agnaldo Pereira Cedenho | 2016 | Asian Journal of Andrology2016，18，2： | 2 |
| 2 | Hypogonadotropic hypogonadism revisited 显示文摘 | Fraietta R Zylberstejn DS Esteves SC | 2013 | Clinics ( Sao Paulo)2013，68，1： | 1 |
| 3 | Fair per-flow multi-step schedu- ler in a new Internet DiftServ node architecture 显示文摘 | Paolo Dini Guido Fraietta Dario Pompili | 2010 | Scientific Commons2010，，： | 1 |
| 4 | Adoptive immunotherapy for cancer or viruses显示文摘 | Maus MV Fraietta JA Levine BL | 2014 | Annu Rev Immunol2014，32，： | 1 |
| 5 | Hypogonadotropic hypogonadism revisited 显示文摘 | Fraietta R Zylberstejn DS Esteves SC | 2013 | Clinics ( Sao Paulo )2013，68，1： | 1 |
| 6 | Hypogonadotropic hypogonadism revisited显示文摘 | Fraietta R Zylberstejn DS Esteves SC | 2013 | Clinics (Sao Paulo)2013，68，1： | 1 |
| 7 | Distinct Signaling of Coreceptors Regulates Specific Metabolism Pathways and Impacts Memory Development in CAR T Cells显示文摘 | Omkar U. Kawalekar Roddy S. O’Connor Joseph A. Fraietta Lili Guo Shannon E. McGettigan Avery D. Posey Prachi R. Patel Sonia Guedan John Scholler Brian Keith Nathaniel Snyder Ian Blair Michael C. Milone Carl H. June | 2016 | Immunity2016，，2： | 1 |
| 8 | Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leu- kemia 显示文摘 | Fraietta JA Beckwith KA Patel PR etal | 2016 | Blood2016，127，9： | 1 |
| 9 | Hypogonadotropic hypogon- adism revisited显示文摘 | Fraietta R Zylberstejn DS Esteves SC | 2013 | Clinics (Sao Paulo)2013，68，1： | 1 |
| 10 | Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia 显示文摘 | Fraietta JA Beckwith KA Patel PR | 2016 | Blood2016，127，9： | 1 |
| 11 | Adoptive im- munotherapy for caneer or viruses显示文摘 | MAUS M V FRAIETTA J A LEVINE B L | 2014 | Ann Rev Immunol2014，32，： | 1 |
| 12 | Engineered T Cell Therapies from a Drug Development Viewpoint显示文摘Cancer is one of the leading causes of death worldwide. Recent advances in cellular therapy have demonstrated that this platform has the potential to give patients with certain cancers a second chance at life. Unlike chemical compounds and proteins, cells are living, self-replicating drugs that can be engineered to possess exquisite specificity. For example, T cells can be genetically modified to express chimeric antigen receptors (CARs), endowing them with the capacity to recognize and kill tumor cells and form a memory pool that is ready to strike back against persisting malignant cells. Anti-CD19 chimeric antigen receptor T cells (CART19s) have demonstrated a remarkable degree of clinical efficacy for certain malignancies. The process of developing CART19 essentially follows the conventional “one gene, one drug, one disease” paradigm derived from Paul Ehrlich’s “magic bullet” concept. With major players within the pharmaceutical industry joining forces to commercialize this new category of “living drugs,” it is useful to use CART19 as an example to examine the similarities and differences in its development, compared with that of a conventional drug. In this way, we can assimilate existing knowledge and identify the most effective approach for advancing similar strategies. This article reviews the use of biomarker-based assays to guide the optimization of CAR constructs, preclinical studies, and the evaluation of clinical efficacy;adverse effects (AEs);and CART19 cellular kinetics. Advanced technologies and computational tools that enable the discovery of optimal targets, novel CAR binding domains, and biomarkers predicting clinical response and AEs are also discussed. We believe that the success of CART19 will lead to the development of other engineered T cell therapies in the same manner that the discovery of arsphenamine initiated the era of synthetic pharmaceuticals. | Fang Chen Joseph A. Fraietta Carl H. June Zhongwei Xu J. Joseph Melenhorst Simon F. Lacey | 2019 | Engineering2019，5，1： | 0 |
您所在的机构暂未开通此部分的功能，请联系管理员